Sector Expert: Mark Breidenbach

Oppenheimer & Co.

Mark Breidenbach is an Executive Director and Senior Analyst with Oppenheimer & Co. covering emerging biotechnology. Previously Mark was at Roth Capital Partners as a lead Analyst covering Biotechnology and prior to that was a Managing Director and Senior Biotechnology Analyst at H.C. Wainwright & Co.. Prior to his Wall Street career, Mark was a Locum Scientist at Nature Publishing Group, and an Associate Specialist in Glycoproteomics and Metabolic Engineering at the Department of Chemistry, University of California Berkeley. Mark holds a Ph.D. in Molecular and Cellular Physiology from Stanford University, a M. Phil. from the Department of Molecular Biophysics and Biochemistry at Yale University, and a dual B.A. in Biology and Chemistry from Cornell University.



Recent Quotes

— Mark Breidenbach, H.C. Wainwright & Co. (3/31/16)
more >

"CANF's Phase 3 CF101 trial in RA could begin enrollment in Q2/16."

— Mark Breidenbach, H.C. Wainwright & Co. (1/7/16)
more >

"CANF is slated to initiate two pivotal studies in 2016."

— Mark Breidenbach, H.C. Wainwright & Co. (11/30/15)
more >

"Data show CANF's CF102 has activity in an animal model of NASH."

— Mark Breidenbach, H.C. Wainwright & Co. (11/24/15)
more >

"RXII is an underappreciated innovator with long-term upside."

— Mark Breidenbach, H.C. Wainwright & Co. (11/13/15)
more >

"RXII is an underappreciated innovator with upside long term."

— Mark Breidenbach, H.C. Wainwright & Co. (10/19/15)
more >

"RXII now may proceed with IRB submission for its Phase 1/2 AMD study."

— Mark Breidenbach, H.C. Wainwright & Co. (9/1/15)
more >

"CANF is finalizing protocols for the next trials of CF101 in RA."

— Mark Breidenbach, H.C. Wainwright & Co. (8/31/15)
more >



Due to permission requirements, not all quotes are shown.